Skip to Content

Patients with malignant pleural mesothelioma continue to benefit from immunotherapy combination

CheckMate 743 study confirms that combination treatment with nivolumab and ipilimumab prolongs overall survival in patients with unresectable malignant pleural mesothelioma

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top